Company intelligence / Profile preview

SpeeDx

Sydney/Eveleigh, NSW, Australiaspeedx.io ↗

Ownership: Private
Employees: ~167
Development stage: Commercial

Overview

SpeeDx has commercialized a portfolio of multiplex molecular diagnostics for STIs, antibiotic resistance markers, and respiratory diseases. Their InSignia™ rapid test for chlamydia and gonorrhea can detect infection as well as antibiotic susceptibility. The company’s products are used globally to improve patient management by providing actionable information beyond simple pathogen detection.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Device (diagnostic device)PCR-based diagnostic technology (Polymerase chain reaction)Isothermal amplification technology
Industry: Molecular Diagnostics

Partnerships

Microbix Biosystems Inc.CARB-X funding partnership for development of rapid point-of-care STI diagnostics

Beyond the preview

Go deeper on SpeeDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpeeDx.

Explore the full profile